Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors: Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis
- PMID: 34148729
- DOI: 10.1016/j.ejca.2021.04.046
Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors: Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis
Conflict of interest statement
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Comment in
-
Response to letter entitled: 'Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors'.Eur J Cancer. 2021 Aug;153:272-273. doi: 10.1016/j.ejca.2021.05.028. Epub 2021 Jun 18. Eur J Cancer. 2021. PMID: 34154880 No abstract available.
Comment on
-
Hematological immune related adverse events after treatment with immune checkpoint inhibitors.Eur J Cancer. 2021 Apr;147:170-181. doi: 10.1016/j.ejca.2021.01.013. Epub 2021 Mar 9. Eur J Cancer. 2021. PMID: 33706206
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
